Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 3/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 5/20 | 0.36 |
| ▸ | IDH1 | O75874 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25138284 | 0.90 | ITGB3 (0.40) | PYGLPOLBALOX15RORCITGB3 | |
| SCHEMBL25138407 | 0.89 | ESR1 (0.40) | POLBESR1ITGB3ITGA2BMAPT | |
| SCHEMBL29978756 | 0.89 | ESR1 (0.40) | POLBESR1ITGB3ITGA2BMAPT | |
| SCHEMBL25138380 | 0.89 | KMT2A (0.43) | PYGLRORCITGB3ITGA2BMAPT | |
| SCHEMBL29979296 | 0.89 | KMT2A (0.43) | PYGLRORCITGB3ITGA2BMAPT | |
| SCHEMBL25138345 | 0.88 | ESR1 (0.39) | PYGLPOLBALOX15RORCESR1 | |
| SCHEMBL29978957 | 0.86 | PIK3C2A (0.44) | PYGLPOLBALOX15RORCESR1 | |
| SCHEMBL28914121 | 0.86 | PIK3C2A (0.44) | PYGLPOLBALOX15RORCESR1 | |
| SCHEMBL25138334 | 0.85 | ESR1 (0.38) | PYGLPOLBALOX15RORCESR1 | |
| SCHEMBL25138415 | 0.84 | ITGB3 (0.40) | PYGLPOLBALOX15RORCESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | CURADEV PHARMA PVT. LTD. (IN) | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230124361-A1 | SMALL MOLECULE STING ANTAGONISTS | STING1, CGAS, MAVS | PYGL 428/4885POLB 2319/4885ALOX15 366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.